Laboratory-Confirmed Shigellosis in the United States, 1989–2002: Epidemiologic Trends and Patterns

Amita Gupta,1,2,a Christina S. Polyak,2 Richard D. Bishop,3 Jeremy Sobel,2 and Eric D. Mintz2

1Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, 2Foodborne and Diarrheal Diseases Branch, and 3Biostatistics and Information Management Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

During 1989–2002, a total of 208,368 laboratory-confirmed Shigella infections were reported to the Centers for Disease Control and Prevention. Shigella sonnei accounted for 71.7%, Shigella flexneri accounted for 18.4%, Shigella boydii accounted for 1.6%, and Shigella dysenteriae accounted for 0.7% of infections; for 7.6%, no serogroup was reported. National incidence rates ranged from 7.6 cases per 100,000 persons in 1993 to 3.7 cases per 100,000 persons in 1999. Incidence rates for S. boydii, S. dysenteriae, and S. flexneri decreased over the 14-year period by 81%, 83%, and 64%, respectively; S. sonnei rates only decreased by 8%. The highest rates were reported from western states (10.0 cases per 100,000 persons) and among children 1–4 years of age (20.6 cases per 100,000 persons). The female-male S. sonnei incidence rate ratio among 20–39-year-old adults decreased from 2.3 during 1989–1999 to 1.4 during 2000–2002. Approximately 1% of isolates were from extraenteric sources; 0.25% were from blood. S. sonnei remains an important cause of diarrhea in the United States. Prevention efforts that target high-risk groups are needed.

Shigella species are a common cause of bacterial gastroenteritis. It is an important cause of morbidity among young children and is challenging to control, particularly in day-care settings [1]. Clinical illness may vary from asymptomatic infection to severe dysentery [2]. There are 4 major subgroups of Shigella (Shigella boydii, Shigella dysenteriae, Shigella flexneri, and Shigella sonnei) and >40 serotypes identified on the basis of characteristics of the O antigen. Although all Shigella subgroups can cause dysentery, S. sonnei causes generally milder disease than do S. dysenteriae and S. flexneri [3, 4]. Life-threatening complications, such as bacteremia, hemolytic uremic syndrome, and toxic megacolon, and long-term sequelae, such as reactive arthritis, can occur. Unlike non-Typhi Salmonella or Escherichia coli O157:H7, humans are the only natural host for Shigella species. On the basis of national laboratory-based surveillance data for Shigella for 1967–1988, the annual isolation rates ranged from 5.0 cases per 100,000 persons in 1985 to 10.1 cases per 100,000 persons in 1988 (average annual isolation rate, 6.5 cases per 100,000 persons) [5] (Centers for Disease Control [CDC], unpublished data). We reviewed surveillance data for laboratory-confirmed cases of shigellosis in the United States for 1989–2002 to identify recent epidemiologic patterns and trends.

MATERIALS AND METHODS

Since 1964, the Foodborne and Diarrheal Diseases Branch at the CDC has maintained a national laboratory-based surveillance system for shigellosis. Data collected during the period of 1989–2002 were used. In

Clinical Infectious Diseases 2004; 38:1372–7
This article is in the public domain, and no copyright is claimed.
1058-4838/2004/3810-0007
Shigellosis in the United States, 1989–2002

RESULTS

During the period of 1989–2002, a total of 208,368 Shigella isolates were reported to the CDC. The distribution of isolates by subgroup was as follows: S. sonnei, 71.7%; S. flexneri, 18.4%; S. boydii, 1.6%; and S. dysenteriae, 0.7%; 7.6% were of an unknown subgroup (i.e., not reported, not further typed, or untypeable). Nationwide incidence rates of Shigella infection varied during the study period, with an average total annual incidence rate of 5.6 cases per 100,000 US population (figure 1). Rates peaked in 1993 at 7.6 cases per 100,000 persons and decreased to a 14-year low of 3.7 cases per 100,000 persons in 1999. Shigella incidence rates were largely driven by S. sonnei (average annual isolation rate, 4.0 cases per 100,000 persons). S. sonnei accounted for an increasing proportion of all Shigella isolates: 64.1% in 1989 and 83.5% in 2002. Incidence rates per 100,000 population for S. boydii, S. dysenteriae, and S. flexneri decreased over the 12-year period by 81.4%, 82.8%, and 64.2%, respectively, whereas S. sonnei rates only decreased by 8%.

The average incidence rate of Shigella infection per 100,000 population was 10.0 cases (range, 5.2–14.9 cases) in the West, 4.6 cases (range, 2.5–8.4 cases) in the South, 4.5 cases (range, 3.0–6.8 cases) in the Midwest, and 3.9 cases (2.3–5.9 cases) in the Northeast (figure 2). During 1999–2002, the incidence of shigellosis in the West approached the incidence of other regions of the United States. Regional variations were often driven by large increases in S. sonnei infection in individual states. The peak incidence rate in the Northeast in 1991 was due to a large increase in S. sonnei infection in Massachusetts, and the peak incidence in the West in 1995 was due to an increase in S. sonnei infection in California. Although S. sonnei was the predominant subgroup overall, several states had a predominance of S. flexneri in specific years. Hawaii had more S. flexneri infections reported than S. sonnei infections in all years except 1994 and 1999. Nine other states and the District of Columbia also reported more S. flexneri than S. sonnei infections in more than a single year (data not shown).

In 1990, the highest isolation rates were reported from counties with relatively high proportions of urban, poor (20%–100% of residents with income below the poverty line), nonwhite residents (table 1). In 2000, compared with 1990, Shigella isolation rates decreased in urban, semiurban, and rural counties. Shigella isolation rates decreased most dramatically in counties with a relatively high proportion of Native American (5%–100%) or black residents (50%–100%). Decreases were also evident for rural and low-income counties. Isolation rates increased in counties with predominantly Hispanic residents, in counties that were 0%–89% white, and in counties that were 1%–49% black.

Patient age was reported for 140,927 isolates (68%). Children aged 1–4 years had the highest rates of shigellosis, ranging from 28.3 cases per 100,000 persons in 1994 to 12.5 cases per 100,000 persons in 1999 (average incidence rate, 20.6 cases per 100,000 persons) (figure 3). The median age of persons with S. sonnei
infection was 7 years, and the median ages for S. boydii, S. flexneri, and S. dysenteriae infections were 18, 18, and 25 years, respectively. Overall, 34.0% of all Shigella isolates were recovered from children aged <5 years, and 80.0% of these isolates were S. sonnei.

Patient sex was reported for 152,083 isolates (73.0%). The mean sex-specific annual incidence rates for Shigella infection were 4.3 cases per 100,000 women and 3.9 cases per 100,000 men, for a female-to-male incidence rate ratio of 1.1:1. By subgroup, the mean ratio was 1.2:1 for S. sonnei, 0.8:1 for S. flexneri, 1.2:1 for S. boydii, and 0.9:1 for S. dysenteriae. The differences in incidence rates by sex were greatest among adults aged 20–39 years for S. sonnei and S. flexneri infection. During 1989–1999, the incidence of S. sonnei infection was twice as high among women than among men in this age group (rate ratio range, 2.0–2.5). In 2000, a proportionately larger increase in male incidence rates (compared with female incidence rates) occurred, changing the female-to-male rate ratio to 1.4 in 2000, 1.1 in 2001, and 1.6 in 2002. In contrast, the ratio for S. flexneri infection among persons aged 20–39 years was 0.5–0.8 throughout the study period.

For all 4 subgroups, reporting of Shigella isolates demonstrated seasonality, with the largest percentage of reported isolates occurring between July and October and the smallest proportion occurring in January, February, and March.

The specific clinical source of the specimen was reported for 147,901 isolates (71%); 146,277 isolates (99%) were recovered from stool samples. The remaining 1624 isolates (1%) were recovered from the following specimens or sites: urine, 929 (0.63%); blood, 400 (0.27%); wound sites, 159 (0.11%); sputum, 102 (0.07%); gallbladder, 15 (0.01%); ear, 7 (0.005%); CSF, 6 (0.004%); and bone/joint, 6 (0.004%). Higher proportions of S. dysenteriae (0.74%), S. flexneri (0.69%), and S. boydii (0.58%) isolates were recovered from blood samples, compared with S. sonnei (0.19%) (P<.01). The highest blood isolation rates were among persons aged <1 year (0.28 cases per 1,000,000 persons), 1–4 years (0.25 cases per 1,000,000 persons), and >80 years (0.12 cases per 1,000,000 persons). Two percent of all Shigella isolates from persons aged >80 years were recovered from blood samples, compared with 0.4% of all Shigella isolates recovered from persons aged <1 year. Forty percent of the blood isolates were recovered from women. On average, 29 Shigella isolates recovered from blood samples were reported annually (range, 17–46 isolates). Among the 6 isolates recovered from CSF samples, 4 were S. sonnei, 1 was S. flexneri, and 1 was S. boydii. The ages of these persons were 0, 2, 5, 7, 33, and 42 years; 4 were men. Data on clinical presentation and outcome were not available.

**DISCUSSION**

Shigella infection is the third most common cause of bacterial gastroenteritis in the United States, after Campylobacter infection and Salmonella infection and ahead of E. coli O157 infection. Unlike Campylobacter, Salmonella, and E. coli O157 in-

![Figure 2. Incidence rates of Shigella species per 100,000 persons, by geographic region, United States, 1989–2002.](image-url)
Infections, for which food-borne transmission predominates, an estimated 80% of Shigella infections are transmitted from person to person [9]. Approximately 10% of persons with reported culture-confirmed Shigella infections are hospitalized [10]. Our examination of laboratory-confirmed shigellosis identified an average annual incidence of 5.6 cases per 100,000 persons during 1989–2002, a 12% decrease from an average annual incidence rate of 6.4 cases per 100,000 persons during 1968–1988 [5, 11] (CDC, unpublished data). During the study period, the incidence of S. dysenteriae, S. flexneri, and S. boydii infections decreased substantially, but there was little decrease in the incidence of S. sonnei infection [5, 11]. The proportion of all Shigella isolates that were S. sonnei, therefore, increased steadily, continuing a trend evident since 1964, when national surveillance for Shigella began [5, 11, 12]. S. sonnei is the most common subgroup in other industrialized nations, whereas S. flexneri is the most common subgroup in developing nations [13].

During 1989–2002, children aged ≤5 years had the highest rates of shigellosis, followed by those aged 5–9 years. Approximately 80% of these infections were due to S. sonnei. High shigellosis rates in children are attributable to several factors. Young children are unable to practice good personal hygiene and have not yet acquired immunity to S. sonnei. The infectious dose is as low as 10–200 organisms [14], and person-to-person transmission is highly effective. Day-care centers play an important role in the person-to-person spread of shigellosis and its subsequent dissemination in communities [15, 16]. Inadequate hand washing, diapering practices, and fecal contamination of water-play areas, such as kiddie pools, have been associated with S. sonnei transmission in day-care centers [16, 17]. When outbreaks occur in day-care settings, attack rates are high (28%–73%) [18, 19], and secondary transmission of S. sonnei often exceeds 30% in households with young children [16, 20–22]. The high rates of Shigella in the West, particularly California, may be explained in part by the large numbers of young children and day-care centers in this state and a public health system that efficiently detects and reports laboratory-confirmed isolates [23].

Compared with 1990, shigellosis incidence rates decreased markedly among Native American persons and less so among black persons. There is no clear explanation for these findings. However, Native American populations and their health care providers, particularly those who serve in Indian Health Service facilities, have become much more aware of shigellosis during the past decade. In addition, water and sanitation infrastructure may have improved, and prevention measures, such as hand washing campaigns, have been conducted in some Native American communities [24, 25]. The change may also be part of the natural cycle of shigellosis in these communities.

During the period of 1989–1999, women 20–39 years of age were more than twice as likely as men in the same age group to have laboratory-confirmed S. sonnei infection, presumably reflecting the increased risk due to women being the primary caretakers of young children [26]. For 2000–2002, however, the female-to-male incidence rate ratio for S. sonnei among 20–39-year-old adults decreased to between 1.1 and 1.6. This occurred because of a proportionately larger increase in male incidence rates than in female incidence rates. This change occurred irrespective of the fact that California submitted age and sex data on patients with shigellosis for the first time in 2000 (data not shown). We believe that this change occurred, in part, because of increases in S. sonnei among men who have sex with men (MSM), among whom S. flexneri was previously more often reported [27]. It is not known why this subgroup shift has occurred in this population. In 2000–2001, a large outbreak of S. sonnei infection occurred among MSM in California [28]. Other outbreaks of S. sonnei infection in 2000–2001 among MSM were reported from Massachusetts (CDC, unpublished data), New York City (New York City Health Department, unpublished data), Canada, and Australia [29, 30]. Surveillance data from 2003 onward will indicate whether this is a continuing trend.

The most common extraenteric samples from which Shigella isolates were reported was urine. Although some of these isolates may have been fecal contaminants, Shigella has been reported as a cause of urinary tract infection [31]. Isolation of Shigella from blood and CSF specimens is rare [32, 33]. In studies of hospitalized patients with laboratory-confirmed shigellosis, reported prevalence rates of Shigella bacteremia were 0.4%–7.3% [32, 34]. Only 0.25% and 0.005% of Shigella isolate reports submitted to the CDC were from blood and CSF samples, respectively. Shigella septicemia is most common in infants and in persons with malnutrition or immunocompromising conditions, including AIDS [32, 35, 36].
and S. boydii blood isolates were relatively more frequent than S. sonnei, suggesting that these subgroups are more invasive.

Our study has several limitations. Data were obtained from a passive surveillance system for laboratory-confirmed illnesses. Most cases of shigellosis are undiagnosed or diagnosed on clinical grounds alone and unreported. It is estimated that the true burden of shigellosis in the United States is ∼440,000 infections annually [9]. Data on patient race and place of residence at the time of specimen culture were missing for ∼90% of reports. We therefore relied on census data to model epidemiologic trends and patterns for race and ethnicity. In addition, patient sex and age were unknown for ∼30% and 35% of reports, respectively.

During the past 14 years, progress has been made in reducing the incidence of shigellosis in the United States among non-sonnei subgroups; however, S. sonnei remains an important cause of gastroenteritis. Laboratory-based surveillance is important to identify trends in populations at particular risk for shigellosis and to inform priorities for vaccine development. A vaccine that provided protection from infection with S. sonnei and S. flexneri would be particularly useful. Although many approaches to Shigella vaccine development have been attempted, including live attenuated, killed whole-cell, conjugate, proteosome subunit, and ribosomal vaccines, to date, vaccine-induced immunity appears to be serotype specific [13, 37, 38]. No vaccines for Shigella are licensed in the United States. Interventions targeting high-risk groups, such as hand washing gels for preventing transmission in day-care centers and vaccines to protect children against infection with S. sonnei, have the potential to significantly reduce the incidence of shigellosis in the United States.

References


